Dr. Andrew M. Brunner, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 153
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Warren Alpert Medical School of Brown University
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 252646 -
Internal Medicine Physician
MA license L-243818
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- Wentworth-Douglass Hospital Dover, NH
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 153
- Services billed
- 873
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 274 | 56 |
| Established patient office or other outpatient visit, 30-39 minutes | 230 | 63 |
| Established patient office or other outpatient visit, 40-54 minutes | 146 | 50 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 22 |
| Hospital discharge day management, more than 30 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Boston, MA | 35 |
| Omeprazole Other prescribers in Boston, MA | 17 |
| Allopurinol Other prescribers in Boston, MA | 11 |
| Inqovi (decitabine/cedazuridine) | 11 |
| Deferasirox | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 25 payments worth $14,739 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $6,288 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $2,865 |
| Geron Corporation | $2,424 |
| AbbVie Inc. | $1,838 |
| GlaxoSmithKline, LLC. | $825 |
| Celgene Corporation | $292 |
| Daiichi Sankyo Inc. | $133 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Consulting Fee | $11,484 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,200 |
| Food and Beverage | $634 |
| Travel and Lodging | $378 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Sep 18, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $6,081 |
| E.r. Squibb & Sons, L.l.c. Jul 1, 2025 | Consulting Fee | $2,865 |
| Geron Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) IMETELSTAT · HEMATOLOGY | $2,200 |
| AbbVie Inc. Jun 9, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,450 |
| GlaxoSmithKline, LLC. Jul 10, 2025 | Consulting Fee | $725 |
| AbbVie Inc. Jan 24, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $363 |
| Celgene Corporation Dec 5, 2025 | Travel and Lodging travel to Orlando, FL | $197 |
| Syndax Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $150 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Syndax Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $30.60 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $542,537 in research payments for these studies, mostly to the institutions running them.
- A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplasti…
Taiho Oncology, Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - TIM3 Inhibition with MBG453 for Patients with Lower Risk MDS
Novartis Pharmaceuticals Corporation - Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) plus Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Celgene Corporation - Phase II Trial of AZD6738 Monotherapy for Myelodysplastic Syndrome Unresponsive or Intolerant to First Line Therapy
AstraZeneca Pharmaceuticals LP - A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Agios Pharmaceuticals, Inc. - A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Novartis Pharmaceuticals Corporation - Phase II Trial of Immunotherapy with MEDI4736 With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant NSCLC
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.